GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (NAS:AKBA) » Definitions » Cyclically Adjusted FCF per Share

Akebia Therapeutics (Akebia Therapeutics) Cyclically Adjusted FCF per Share : $-1.50 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Akebia Therapeutics's adjusted free cash flow per share for the three months ended in Dec. 2023 was $-0.012. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.50 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-04-27), Akebia Therapeutics's current stock price is $1.34. Akebia Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $-1.50. Akebia Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Akebia Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Akebia Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Cyclically Adjusted FCF per Share Chart

Akebia Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -1.55 -1.50

Akebia Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.55 -1.57 -1.56 -1.54 -1.50

Competitive Comparison of Akebia Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Akebia Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akebia Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Akebia Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Akebia Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.012/129.4194*129.4194
=-0.012

Current CPI (Dec. 2023) = 129.4194.

Akebia Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -2.762 99.695 -3.586
201406 -0.341 100.560 -0.439
201409 -0.286 100.428 -0.369
201412 -0.464 99.070 -0.606
201503 -0.427 99.621 -0.555
201506 -0.456 100.684 -0.586
201509 -0.318 100.392 -0.410
201512 -0.757 99.792 -0.982
201603 0.470 100.470 0.605
201606 -0.746 101.688 -0.949
201609 -0.778 101.861 -0.988
201612 2.498 101.863 3.174
201703 -0.257 102.862 -0.323
201706 0.593 103.349 0.743
201709 -1.176 104.136 -1.462
201712 -0.355 104.011 -0.442
201803 -0.424 105.290 -0.521
201806 0.155 106.317 0.189
201809 -0.224 106.507 -0.272
201812 -1.072 105.998 -1.309
201903 -1.195 107.251 -1.442
201906 -0.341 108.070 -0.408
201909 0.071 108.329 0.085
201912 -0.774 108.420 -0.924
202003 -0.698 108.902 -0.830
202006 0.272 108.767 0.324
202009 -0.190 109.815 -0.224
202012 -0.212 109.897 -0.250
202103 -0.460 111.754 -0.533
202106 -0.391 114.631 -0.441
202109 -0.324 115.734 -0.362
202112 -0.360 117.630 -0.396
202203 -0.121 121.301 -0.129
202206 -0.161 125.017 -0.167
202209 0.184 125.227 0.190
202212 -0.297 125.222 -0.307
202303 -0.095 127.348 -0.097
202306 0.019 128.729 0.019
202309 -0.038 129.860 -0.038
202312 -0.012 129.419 -0.012

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Akebia Therapeutics  (NAS:AKBA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Akebia Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Akebia Therapeutics (Akebia Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
245 First Street, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.
Executives
Ellen Snow officer: SVP, CFO and Treasurer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Michel Dahan officer: SVP, Chief Business Officer C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Nicole R. Hadas officer: SVP, General Counsel, Sec. 20 PILGRAM DRIVE, WINCHESTER MA 01890
David A Spellman officer: SVP, CFO and Treasurer 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Steven Keith Burke officer: SVP, Chief Medical Officer 82 WILLIS ROAD, SUDBURY MA 01776
John P. Butler director, officer: CEO & President C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Violetta Cotreau officer: SVP, Chief Accounting Officer 245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Ron Frieson director 245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Dell Faulkingham officer: CCO C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Leanne M Zumwalt director C/O THE ADVISORY BOARD CO WATERGATGE, 600 NEW HAMPSHIRE AVE NW, WASHINGTON DC 20037
Maxine Gowen director
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Myles Wolf director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Karen L Tubridy officer: SVP, Chief Development Officer ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142